Company: TVRD
Filing Date: 2025-10-07
Form Type: S-1/A
Source: 0001104659-25-097519
Chunk: 313

Company: Tvardi Therapeutics, Inc.
Filing Date: 2025-10-07
Form: S-1/A
Chunk 313
---
 assets consisted of the following as of December 31, 2024 and 2023 (in thousands):

| ​                              
 ​                              | ​ 
 ​ 
 ​ | ​                  
 As of December 31, |    ​ 
 2024 | ​ | ​ |    ​ 
 2023 |
|:-------------------------------|:--|:-------------------|-----:|:--|:--|-----:|
| Licensed patent rights         | ​ | $                  |  826 | ​ | $ |  826 |
| Less: accumulated amortization | ​ |                    | -441 | ​ |   | -378 |
| Total intangible assets, net   | ​ | $                  |  385 | ​ | $ |  448 |

As of December 31, 2024, the expected remaining amortization expense is as follows (in thousands):

| ​                       
 Year Ended December 31, 
 2025                    | ​ | ​      
 Amount 
 ​      |   ​ 
  63 |
|:------------------------|:--|:-------|----:|
| 2026                    |   | ​      |  63 |
| 2027                    |   | ​      |  63 |
| 2028                    |   | ​      |  63 |
| 2029                    |   | ​      |  63 |
| Thereafter              |   | ​      |  70 |
| Total                   | ​ | $      | 385 |

F-17

The Company recognized less than $ 0.1million for amortization expense for each of the years ended December 31, 2024 and 2023. Amortization expense is included in research and development expense in the statements of operations.

6.Accrued Expenses

Accrued expenses consisted of the following as of December 31, 2024 and 2023 (in thousands):

| ​                                          
 ​                                          | ​ 
 ​ | ​                  
 As of December 31, |     ​ 
  2024 | ​ | ​ |     ​ 
  2023 |
|:-------------------------------------------|:--|:-------------------|------:|:--|:--|------:|
| Accrued research and development expenses  | ​ | $                  | 5,172 | ​ | $ |   518 |
| Accrued employee compensation and benefits | ​ |                    | 1,142 | ​ |   |   942 |